Patrick H Ruane, PhD
Chief Operating Officer
Bio:
Patrick has over twenty years of experience advancing sustained-release drug delivery systems across therapeutic areas including cardiovascular, ophthalmology, gastrointestinal, ENT, transdermal, and surgical applications. His expertise lies in controlled release of active pharmaceutical ingredients from biodegradable polymeric platforms within drug–device combination products.
He has held senior leadership roles driving innovation in the pharmaceutical industry, including Chief Technology Officer at Allay Therapeutics and Chrono Therapeutics, and Vice President of R&D at CV Ingenuity (later acquired by Covidien). Earlier roles at Xtent Inc., Cook Group, and Navigant Biotechnologies broadened his experience developing next-generation delivery systems.
Patrick’s career reflects a commitment to improving patient outcomes through novel technologies that provide sustained therapeutic benefit. His multidisciplinary knowledge enables him to address complex challenges across diverse medical fields.
Trained as a physical-organic photochemist, Patrick has contributed extensively to both academic and patent literature. He earned undergraduate degrees in chemistry from Galway-Mayo Institute of Technology and Trinity College Dublin, followed by a Ph.D. from University College Dublin. Postdoctoral fellowships at the University of Toronto, Johns Hopkins University, and The Ohio State University expanded his expertise in photochemistry, with research spanning reactive intermediates, controlled nitric oxide release, and pathogen inactivation in blood products.
Patrick’s ability to translate advanced photochemistry into practical biomedical applications highlights his unique blend of scientific depth and translational impact. His work continues to shape the evolution of sustained-release drug delivery, offering new possibilities for patient care and improved treatment outcomes.